Simply Wall St.
Guardant Health (GH) Is Down 8.9% After Issuing 2026 Guidance And New Equity Shelf Registration – Has The Bull Case Changed?
➖
AI Sentiment
Neutral
4/10
- Home
- GH
as of 02-27-2026 3:35pm EST
$94.00
$3.97
-4.05%
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 13.3B | IPO Year: | 2018 |
| Target Price: | $117.80 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.32 | EPS Growth: | 6.74 |
| 52 Week Low/High: | $34.91 - $120.74 | Next Earning Date: | 05-11-2026 |
| Revenue: | $982,021,000 | Revenue Growth: | 32.88% |
| Revenue Growth (this year): | 29.73% | Revenue Growth (next year): | 27.71% |
| P/E Ratio: | -29.48 | Index: | N/A |
| Free Cash Flow: | -233066000.0 | FCF Growth: | N/A |
AI-Powered GH Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 75.80%
75.80%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Guardant Health Inc. (GH)
Monroe Terilyn J.
Sell
Chief People Officer
GH Jan 21, 2026
Avg Cost/Share
$113.84
Shares
8,571
Total Value
$977,901.82
Owned After
20,990
Monroe Terilyn J.
Sell
Chief People Officer
GH Jan 7, 2026
Avg Cost/Share
$112.60
Shares
10,031
Total Value
$1,124,279.50
Owned After
20,990
Tariq Musa
Sell
Director
GH Dec 17, 2025
Avg Cost/Share
$101.46
Shares
116
Total Value
$11,769.36
Owned After
7,993
SEC Form 4
Chudova Darya
Sell
Chief Technology Officer
GH Dec 15, 2025
Avg Cost/Share
$104.04
Shares
5,451
Total Value
$567,131.85
Owned After
7,012
SEC Form 4
Eltoukhy Helmy
Sell
Co-Chief Executive Officer
GH Dec 15, 2025
Avg Cost/Share
$103.91
Shares
90,565
Total Value
$9,402,220.02
Owned After
2,053,763
Kalia Kumud
Sell
Chief Information Officer
GH Dec 8, 2025
Avg Cost/Share
$104.60
Shares
2,000
Total Value
$209,204.20
Owned After
22,365
SEC Form 4
Chudova Darya
Sell
Chief Technology Officer
GH Dec 8, 2025
Avg Cost/Share
$105.52
Shares
22,935
Total Value
$2,417,979.82
Owned After
7,012
Talasaz AmirAli
Sell
Co-Chief Executive Officer
GH Dec 8, 2025
Avg Cost/Share
$105.18
Shares
100,000
Total Value
$10,505,473.54
Owned After
172,463
Hidalgo Medina Manuel
Sell
Director
GH Dec 8, 2025
Avg Cost/Share
$105.00
Shares
1,250
Total Value
$131,250.00
Owned After
797
Monroe Terilyn J.
Sell
Chief People Officer
GH Dec 1, 2025
Avg Cost/Share
$106.40
Shares
55,167
Total Value
$5,846,163.49
Owned After
20,990
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Monroe Terilyn J. | GH | Chief People Officer | Jan 21, 2026 | Sell | $113.84 | 8,571 | $977,901.82 | 20,990 | |
| Monroe Terilyn J. | GH | Chief People Officer | Jan 7, 2026 | Sell | $112.60 | 10,031 | $1,124,279.50 | 20,990 | |
| Tariq Musa | GH | Director | Dec 17, 2025 | Sell | $101.46 | 116 | $11,769.36 | 7,993 | |
| Chudova Darya | GH | Chief Technology Officer | Dec 15, 2025 | Sell | $104.04 | 5,451 | $567,131.85 | 7,012 | |
| Eltoukhy Helmy | GH | Co-Chief Executive Officer | Dec 15, 2025 | Sell | $103.91 | 90,565 | $9,402,220.02 | 2,053,763 | |
| Kalia Kumud | GH | Chief Information Officer | Dec 8, 2025 | Sell | $104.60 | 2,000 | $209,204.20 | 22,365 | |
| Chudova Darya | GH | Chief Technology Officer | Dec 8, 2025 | Sell | $105.52 | 22,935 | $2,417,979.82 | 7,012 | |
| Talasaz AmirAli | GH | Co-Chief Executive Officer | Dec 8, 2025 | Sell | $105.18 | 100,000 | $10,505,473.54 | 172,463 | |
| Hidalgo Medina Manuel | GH | Director | Dec 8, 2025 | Sell | $105.00 | 1,250 | $131,250.00 | 797 | |
| Monroe Terilyn J. | GH | Chief People Officer | Dec 1, 2025 | Sell | $106.40 | 55,167 | $5,846,163.49 | 20,990 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
StockStory
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know
📉
AI Sentiment
Negative
2/10
Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
📊
AI Sentiment
Positive
6/10
Barrons.com
Grail’s Stock Dropped 50% on Friday. Investors Still Have High Hopes for the Biotech.
📉
AI Sentiment
Negative
3/10
Medical Device Network
Guardant Health acquires MetaSight amid positive 2026 financial outlook
📈
AI Sentiment
Highly Positive
9/10
Compare GH vs Leading Stocks
See how GH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.